Ultralife Q2 2026: Record Backlog and Margin Expansion Overshadowed by Unremediated Material Weakness
ULBI sits 22% above its 52-week low of $4.9.
Summary
Ultralife's Q2 2026 earnings show a sharp operational rebound with record backlog and margin gains, but the filing reveals an ongoing unremediated material weakness in internal controls — a governance concern that tempers the positive results.
Key Events · Earnings and Guidance · ULBI
-
Material Weakness Remains Unremediated
Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to an ongoing material weakness in internal control over financial reporting. Remediation efforts are still in progress, with IT general controls deficiencies yet to be fully addressed.
-
Q2 Net Income Triples on Tariff Refund
Net income attributable to Ultralife was $2.5 million ($0.15/share) vs $0.9 million ($0.05/share) a year ago. A $1.1 million IEEPA tariff refund reduced cost of goods sold, contributing 230 basis points to the 500-basis-point gross margin expansion.
-
Record Backlog of $117.5 Million
Total backlog exiting Q2 2026 reached $117.5 million, the highest in company history, up from $84.5 million a year earlier, signaling strong future revenue visibility.
-
Gross Margin Jumps to 28.9%
Consolidated gross margin improved from 23.9% to 28.9%, driven by favorable product mix and the tariff refund. Battery & Energy Products margin rose 470 basis points to 28.3%.
Analysis · ULBI · Manufacturing
Ultralife delivered a strong operational quarter — net income tripled year-over-year to $2.5 million, gross margins surged 500 basis points to 28.9% thanks to a $1.1 million tariff refund and favorable mix, and backlog hit a record $117.5 million. However, the company disclosed that its previously identified material weakness in internal controls remains unremediated, and its disclosure controls are still not effective. For a small-cap manufacturer, an open material weakness is a serious governance red flag that undermines confidence in financial reporting, even as the underlying business improves.
At the time of this filing, ULBI was trading at $5.98 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $88.6M. The 52-week trading range was $4.90 to $8.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.